Amgen has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market.
Cycle Pharmaceuticals announced that it has signed an agreement with Catalent to develop innovative formulations targeting rare disease patients.
Pandion Therapeutics has signed a license and collaboration deal worth up to $795m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmune diseases of the pancreas.
Gilead Sciences and Glympse Bio announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical programme.
Takeda Pharmaceutical has signed a deal worth up to $420m with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise the latter’s CNP-101 (TAK-101).
Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the acquisition of Encycle Therapeutics, a private Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides exhibiting enhanced drug-like properties.
Verseau Therapeutics, Inc. (“Verseau”) launched with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
Alexion Pharmaceuticals has agreed to acquire clinical-stage biopharmaceutical company Achillion Pharmaceuticals in a deal valued at around $930m.
CRISPR Therapeutics and KSQ Therapeutics have signed license agreement to advance their respective cell therapy programmes in oncology.
Belgium-based biopharmaceutical firm UCB has agreed to acquire US-based clinical-stage biopharmaceutical company Ra Pharmaceuticals in a deal valued at around $2.1bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.